Literature DB >> 2013837

The pharmacokinetics and pharmacodynamics of ketamine in dogs anesthetized with enflurane.

I M Schwieger1, F Szlam, C C Hug.   

Abstract

The plasma concentration vs. anesthetic effect relationships for ketamine are not well known. It is desirable to establish stable and predictable drug concentrations in plasma (and brain) in order to define such relationships. As a prelude to pharmacodynamic studies, we investigated ketamine pharmacokinetics in eight dogs anesthetized with enflurane and correlated ketamine concentration in plasma (KET) with its ability to reduce the enflurane concentration required for anesthesia (enflurane EC50: MAC--the end-tidal concentration at which half the dogs moved in response to clamping of the tail and half did not move). Four dogs (Group 1) received ketamine 10 mg/kg iv over 30 sec. Blood for determination of KET was collected repeatedly over the 5-h period following injection. Based on the pharmacokinetic parameters determined for Group 1, four dogs in Group 2 received ketamine as a continuous infusion of 300 micrograms.kg-1.min-1 for 5 hr accompanied by an initial loading dose (26 mg/kg administered over 20 min) designed to produce a stable KET of 20 micrograms/ml of plasma. Enflurane MAC and KET were determined regularly during the infusion and for 5 hr after discontinuation of the infusion. There were no significant differences in the following pharmacokinetic parameters determined for Group 1 vs. Group 2: t1/2 beta = 122 +/- 9 vs. 141 +/- 40 min (mean +/- SD) and CL = 18.1 +/- 5.9 vs. 13.9 +/- 2.5 ml.kg-1.min-1, respectively. When administered as a continuous infusion (Group 2), KET remained relatively stable at 22.1 +/- 4.6 micrograms/ml for 5 hr. The degree of MAC reduction remained relatively stable at 73% during the continuous infusion. Finally, the enflurane MAC reduction vs. KET was established over a wide range of plasma concentrations in 4 additional dogs (Group 3). This study determined that the pharmacokinetics of ketamine were consistent under two different experimental conditions and demonstrated the relationship between plasma concentration and anesthetic effect in the dog.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2013837     DOI: 10.1007/bf01073866

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  13 in total

1.  Pharmacokinetics of ketamine in man.

Authors:  J Wieber; R Gugler; J H Hengstmann; H J Dengler
Journal:  Anaesthesist       Date:  1975-06       Impact factor: 1.041

2.  Ketamine--its pharmacology and therapeutic uses.

Authors:  P F White; W L Way; A J Trevor
Journal:  Anesthesiology       Date:  1982-02       Impact factor: 7.892

3.  Gas chromatographic analysis of ketamine and norketamine in plasma and urine: nitrogen-sensitive detection.

Authors:  R L Stiller; P G Dayton; J M Perel; C C Hug
Journal:  J Chromatogr       Date:  1982-11-12

4.  Humaneness of anesthetic induction technique questioned.

Authors:  B A Gilroy
Journal:  Anesthesiology       Date:  1983-09       Impact factor: 7.892

5.  Pharmacokinetics and analgesic effect of ketamine in man.

Authors:  J A Clements; W S Nimmo
Journal:  Br J Anaesth       Date:  1981-01       Impact factor: 9.166

6.  Plasma levels of ketamine and two of its metabolites in surgical patients using a gas chromatographic mass fragmentographic assay.

Authors:  E F Domino; E K Zsigmond; L E Domino; K E Domino; S P Kothary; S E Domino
Journal:  Anesth Analg       Date:  1982-02       Impact factor: 5.108

7.  Measurement of liver blood flow by galactose clearance.

Authors:  S S Hanna
Journal:  Can J Surg       Date:  1984-05       Impact factor: 2.089

8.  The anesthetic potency of fentanyl in terms of its reduction of enflurane MAC.

Authors:  M R Murphy; C C Hug
Journal:  Anesthesiology       Date:  1982-12       Impact factor: 7.892

9.  Pharmacokinetics of ketamine and two metabolites in the dog.

Authors:  J S Kaka; W L Hayton
Journal:  J Pharmacokinet Biopharm       Date:  1980-04

10.  Effects of enflurane and halothane on liver blood flow and oxygen consumption in the greyhound.

Authors:  R L Hughes; D Campbell; W Fitch
Journal:  Br J Anaesth       Date:  1980-11       Impact factor: 9.166

View more
  6 in total

1.  Kinetics of ketamine plasma and urine metabolite levels following intravenous administration in the dog.

Authors:  P Roncada; A Zaghini; C Riciputi; N Romagnoli; A Spadari
Journal:  Vet Res Commun       Date:  2003-09       Impact factor: 2.459

2.  Influence of prior determination of baseline minimum alveolar concentration (MAC) of isoflurane on the effect of ketamine on MAC in dogs.

Authors:  Giacomo Gianotti; Alexander Valverde; Ron Johnson; Melissa Sinclair; Thomas Gibson; Doris H Dyson
Journal:  Can J Vet Res       Date:  2014-07       Impact factor: 1.310

3.  Antinociceptive effects, metabolism and disposition of ketamine in ponies under target-controlled drug infusion.

Authors:  M Knobloch; C J Portier; O L Levionnois; R Theurillat; W Thormann; C Spadavecchia; M Mevissen
Journal:  Toxicol Appl Pharmacol       Date:  2006-07-03       Impact factor: 4.219

4.  Effects of ketamine and lidocaine in combination on the sevoflurane minimum alveolar concentration in alpacas.

Authors:  Patricia Queiroz-Williams; Thomas J Doherty; Anderson F da Cunha; Claudia Leonardi
Journal:  Can J Vet Res       Date:  2016-04       Impact factor: 1.310

5.  Stereoselective biotransformation of ketamine in equine liver and lung microsomes.

Authors:  A Schmitz; C J Portier; W Thormann; R Theurillat; M Mevissen
Journal:  J Vet Pharmacol Ther       Date:  2008-10       Impact factor: 1.786

6.  Plasma Concentration Rise after the Intramuscular Administration of High Dose Medetomidine (0.13 mg/kg) for Semen Collection in Cats.

Authors:  Noemi Romagnoli; Carlotta Lambertini; Daniele Zambelli; Marco Cunto; Giulia Ballotta; Andrea Barbarossa
Journal:  Vet Sci       Date:  2020-02-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.